Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (OMER)
NASDAQ:OMER
OMER Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.61 - $13.60
Previous CloseN/A
Volume193.12K
Average Volume (3M)492.70K
Market Cap
$556.90M
Enterprise Value$540.34M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Feb 26, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding57,949,760
10 Day Avg. Volume424,247
30 Day Avg. Volume492,699
Standard Deviation0.35
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)354.52
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.74
Enterprise Value/Ebitda-3.30
Forecast
1Y Price Target
$21.03Price Target Upside129.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPlans to advance OMS906 to phase 3 development in both PNH and C3G.
Regulatory ProgressOMER plans to proceed with a BLA resubmission and an EMA filing based on positive statistical analysis results.
Bears Say
Financial ConcernsConcerns are noted due to OMER ending with cash of ~$123MM, debt of ~$164MM, and a 'going concern' in its 10Q filing.
Regulatory ChallengesSkepticism remains over FDA approval for narsoplimab due to the lack of new clinical data and the lengthy regulatory process.
Uncertain FutureThe uncertain path forward for OMER contributes to maintaining a Hold rating.
---
Ownership Overview
9.70%
Insiders
8.68% Mutual Funds
10.12% Other Institutional Investors
61.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $2.61 and its highest was $13.60 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $556.90M.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Nov 13, 2024. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.705 by $0.145.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -0.69.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 57,949,760 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.705. Following the earnings report the stock price went up 65.871%.
Which hedge fund is a major shareholder of Omeros Corp?
Among the largest hedge funds holding Omeros Corp’s share is Sheaff Brock Investment Advisors LLC. It holds Omeros Corp’s shares valued at 0.
---
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.03 (129.08% Upside)
$21.03 (129.08% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 60.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.5%
Last 30 Days ▼ 19.4%
Last 30 Days ▼ 19.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.22%
12-Months-Change
Fundamentals
Return on Equity
87.26%
Trailing 12-Months
Asset Growth
-36.45%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
---
OMER Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development programs, cost reductions, and regulatory advancements, particularly for narsoplimab and zaltenibart. However, financial challenges remain with decreased cash reserves and declining OMIDRIA sales. Despite these challenges, the sentiment leans positive due to strategic advancements and potential new revenue streams.Read More>---
OMER Stock 12 Month Forecast
Average Price Target
$21.03
▲(129.08% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Neurocrine
―
Supernus Pharmaceuticals
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering OMER
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+73.32%
reiterated a buy rating 11 months ago
Copying Stephen Brozak's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +73.32% per trade.
---